samedan logo
 
 
 
spacer
home > ebr > autumn 2009 > strategies and innovations: antibody purification
PUBLICATIONS
European Biopharmaceutical Review

Strategies and Innovations: Antibody Purification

 

Antibodies have been a major focus in biopharmaceutical research and development for the last two decades, ever since the first development of a process for the isolation of monoclonal antibodies (mAbs) in the 1970s. Following the FDA approval of the first therapeutic mAb in 1986 (1), and as a result of significant technological advances in the 1990s, mAbs and antibody fragments are now an increasingly important class of drugs. Reports from 2008 indicate that there are currently over 200 mAb candidates in clinical development (2), with 24 mAbs having been approved for therapeutic use (1).

Therapeutic antibodies in clinical use today cover a broad range of indications, including cancer, chronic inflammatory diseases, transplant rejection, infectious diseases and cardiovascular disease. The majority of antibody drugs are full-sized IgG forms, although there is increased interest in the use of antibody fragments, with three fragment-based drugs being approved for therapeutic use in the US.

ANTIBODY CLASSES, STRUCTURE AND FUNCTION

Human antibodies are grouped into five different isotypes (IgG, IgE, IgD, IgM and IgA) and then split further into sub-classes (IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) (see Figure 1). The different isotypes have distinct functions within the body.

Antibodies are relatively large globular proteins, consisting of two heavy chains (which define the isotype and subclass) and two light chains.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Frank Detmers is Director of Ligand Application at BAC. In 2001, he received his PhD at the department of Molecular Microbiology at the University of Groningen (the Netherlands). He worked as a postdoctoral researcher at the Department of Cell Physiology at the Nijmegen Center of Molecular Life Sciences (NCMLS, Nijmegen, the Netherlands). He joined BAC in 2004 and the focus of his work is immobilisation of affinity ligands on solid supports and the development of applications of ligands in healthcare.

After receiving a Bachelors degree in Biochemistry, Pim Hermans joined the R&D department at Holland Biotechnology. In this group, he carried out research on the production and purification of recombinant cytokines and monoclonal antibodies for diagnostic and research purposes. In 1993, Pim joined the Bio-Immunochemistry group at Unilever-Bestfoods, where he was involved in the early development and exploration of camelid derived single domain antibodies (VHHs). Pim joined BAC in 2002. As Director of the Ligand Discovery Department, Pim is responsible for the development of VHH-based affinity ligands for applications in process, and analytical affinity chromatography.

spacer
Frank Detmers
spacer
spacer
spacer
Pim Hermans
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ACG ‘Makes it Better’

ACG is consolidating its founding values of caring, collaboration and progressiveness in a comprehensive re-brand. As one of the world's leading suppliers of fully integrated solutions to the global pharmaceutical and nutraceutical industry, ACG is taking this opportunity to share the message at the heart of its operation - ‘Make it Better’
More info >>

White Papers

Inhaler Adherence: Exploring Key Factors

Aptar Pharma

Aptar Pharma recently hosted an expert panel roundtable on “Inhaler Adherence”. This international scientific forum was held in Paris, France on November 29th 2013. The roundtable was organized to explore and exchange views on the issues which may influence inhaler adherence/ compliance with a particular focus on asthma and C.O.P.D. therapies and their corresponding inhaler devices (MDIs, DPIs).
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement